Prevention of stent thrombosis with reduced dose of prasugrel in two patients undergoing treatment of cerebral aneurysms with pipeline embolisation devices

Journal of NeuroInterventional Surgery

Volumn 5, Issue 5, 2013, Pages

  Morgan Jones, G ^a   Twilla, Jennifer D ^a   Hoit, Daniel A ^b   Arthur, Adam S ^b  

^a METHODIST UNIVERSITY HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; PRASUGREL;

ADULT; ANGIOGRAPHY; ARTICLE; BRAIN HEMORRHAGE; BRAIN SURGERY; CASE REPORT; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INTERNAL CAROTID ARTERY ANEURYSM; INTRACRANIAL STENTING; LOADING DRUG DOSE; MEDICAL DEVICE; PIPELINE EMBOLIZATION DEVICE; PRIORITY JOURNAL; STENT THROMBOSIS; SUBARACHNOID HEMORRHAGE; TREATMENT RESPONSE; VASCULAR ACCESS;

ANEURYSM; PHARMACOLOGY; PLATELETS; STENT;

CAROTID ARTERY, INTERNAL, DISSECTION; CEREBRAL ANGIOGRAPHY; EMBOLIZATION, THERAPEUTIC; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTRACRANIAL ANEURYSM; MIDDLE AGED; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P2Y12; STENTS; THIOPHENES; THROMBOSIS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 84882293007     PISSN: 17598478     EISSN: 17598486     Source Type: Journal    
DOI: 10.1136/neurintsurg-2012-010482     Document Type: Article

References (12)

1. Nelson PK, Lylyk P, Szikora I, et al. The pipeline embolization device for the intracranial treatment of aneurysms trial. AJNR Am J Neuroradiol 2011;32:34-40.
2. Prabhakaran S, Wells KR, Lee VH, et al. Prevalence and risk factors for aspirin and clopidogrel resistance in cerebrovascular stenting. AJNR Am J Neuroradiol 2008;29:281-5.
3. Chaturvedi S, Yadav JS. The role of antiplatelet therapy in carotid stenting for ischemic stroke prevention. Stroke 2006;37:1572-7.
4. Lutsep HL, Barnwell S, Mawad DC, et al. Stenting of Symptomatic Atherosclerotic Lesions in the Vertebral or Intracranial Arteries (SSYLVIA): study results. Stroke 2004;35:1388-92.
5. Kang HS, Kwon BJ, Kim JE, et al. Preinterventional clopidogrel response variability for coil embolization of intracranial aneurysms: clinical implications. AJNR Am J Neuroradiol 2010;31:1206-10.
6. McKevitt FM, Randall MS, Cleveland TJ, et al. The benefits of combined anti-platelet treatment in carotid artery stenting. Eur J Vasc Endovasc Surg 2005;29:522-7.
7. Bhatt DL, Kapadia SR, Bajzer CT, et al. Dual antiplatelet therapy with clopidogrel and aspirin after carotid artery stenting. J Invasive Cardiol 2001;13:767-71.
8. Buonamici P, Marcucci R, Migliorini A, et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 2007;49:2312-17.
9. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-15.
10. Leslie-Mazwi TM, Chandra RV, Oh DC, et al. Novel use of prasugrel for intracranial stent thrombosis. J Neurointerv Surg 2011;3:358-60.
11. Akbari SH, Reynolds MR, Kadkhodayan Y, et al. Hemorrhagic complications after prasugrel (effient) therapy for vascular Neuro Interventional procedures. J Neuro Intervent Surg 2013;5:344-5.
12. Erlinge D, Ten Ber J, Foley D, et al. Prasugrel 5mg in low body weight patients reduces platelet reactivity to a similar extent as prasugrel 10 mg in higher body weight patients: results from the feather trial. J Am Col Cardiol 2012;59:E341.